Mon. 11 Mar 2024, 8:15am ET
Benzinga
Biotech, News, Health Care, General
Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose.